The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.
作者信息
Dizdarevic S, Tulchinsky M, McCready V R, Mihailovic J, Vinjamuri S, Buscombe J R, Lee S T, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, Virgolini I
机构信息
Department of Imaging and Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton and Sussex Medical School, Royal Sussex County Hospital, Brighton, UK.
Radiology Department, Nuclear Medicine Section, Penn State University, Milton S. Hershey Medical Center, USA.
出版信息
World J Nucl Med. 2019 Apr-Jun;18(2):123-126. doi: 10.4103/wjnm.WJNM_117_18.
Abstract
摘要
相似文献
1
The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.世界放射性药物与分子治疗协会关于分化型甲状腺癌初始放射性碘治疗的立场声明。
World J Nucl Med. 2019 Apr-Jun;18(2):123-126. doi: 10.4103/wjnm.WJNM_117_18.
2
Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.放射性碘治疗分化型甲状腺癌后的第二原发恶性肿瘤风险。
Surgery. 2012 Jun;151(6):844-50. doi: 10.1016/j.surg.2011.12.019. Epub 2012 Feb 15.
3
Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.栓塞联合放射性碘治疗分化型甲状腺癌骨转移
Clin Endocrinol (Oxf). 2000 May;52(5):653-9. doi: 10.1046/j.1365-2265.2000.00998.x.
4
A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?争议问题：放射性碘治疗对分化型甲状腺癌是否有利？
J Nucl Med. 2018 Aug;59(8):1195-1201. doi: 10.2967/jnumed.117.191338. Epub 2018 May 10.
5
Variants and pitfalls on radioiodine scans in pediatric patients with differentiated thyroid carcinoma.分化型甲状腺癌患儿放射性碘扫描的变异与陷阱
Pediatr Radiol. 2016 Oct;46(11):1579-89. doi: 10.1007/s00247-016-3655-2. Epub 2016 Aug 3.
6
Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?放射性碘治疗对非碘聚集性分化型甲状腺癌有不利影响吗？
Clin Endocrinol (Oxf). 2002 Jul;57(1):117-24. doi: 10.1046/j.1365-2265.2002.01574.x.
7
Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age.107例分化型甲状腺癌伴初始骨转移患者放射性碘治疗后的结局：副作用及年龄的影响
Eur J Nucl Med. 2001 Feb;28(2):203-8. doi: 10.1007/s002590000420.
8
Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.放射性碘治疗对分化型甲状腺癌且全身碘扫描阴性患者血清甲状腺球蛋白升高的治疗效果。
Nucl Med Commun. 2006 Jul;27(7):567-72. doi: 10.1097/00006231-200607000-00004.
9
Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.仑伐替尼联合放射性碘治疗晚期分化型甲状腺癌：病例报告及文献复习。
World J Surg Oncol. 2019 May 19;17(1):84. doi: 10.1186/s12957-019-1626-4.
10
TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.端粒酶逆转录酶（TERT）启动子突变可预测远处转移性分化型甲状腺癌的碘难治特性。
J Nucl Med. 2017 Feb;58(2):258-265. doi: 10.2967/jnumed.116.180240. Epub 2016 Aug 4.
引用本文的文献
1
Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.放射性碘（碘化物）在分化型甲状腺癌管理中的放射诊断学范例。
Curr Pharm Des. 2020;26(31):3812-3827. doi: 10.2174/1381612826666200605121054.
本文引用的文献
1
European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.2015 年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南的欧洲视角：国际互动研讨会纪要。
Thyroid. 2019 Jan;29(1):7-26. doi: 10.1089/thy.2017.0129. Epub 2019 Jan 7.
2
Why should we be concerned about a "g"?我们为什么要关注一个“g”？
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):519. doi: 10.1007/s00259-018-4204-z. Epub 2018 Nov 6.
3
Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics.手术后分化型甲状腺癌的治疗效果及活动调整后 131I 治疗效果。
Clin Nucl Med. 2019 Jan;44(1):11-20. doi: 10.1097/RLU.0000000000002321.
4
A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer.放射性碘治疗甲状腺癌后恶性肿瘤风险的系统评价和荟萃分析。
Thyroid. 2018 Dec;28(12):1662-1673. doi: 10.1089/thy.2018.0244. Epub 2018 Nov 27.
5
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.低危甲状腺癌患者消融治疗后的结局（ESTIMABL1）：一项随机、3 期、等效性试验的 5 年随访结果。
Lancet Diabetes Endocrinol. 2018 Aug;6(8):618-626. doi: 10.1016/S2213-8587(18)30113-X. Epub 2018 May 26.
6
Controversial Issues in Thyroid Cancer Management.甲状腺癌管理中的争议问题。
J Nucl Med. 2018 Aug;59(8):1187-1194. doi: 10.2967/jnumed.117.192559. Epub 2018 Apr 13.
7
Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy.分化型甲状腺癌的放射性碘治疗：直面关于继发性恶性肿瘤风险的争议性文献所获经验教训
J Nucl Med. 2018 May;59(5):723-725. doi: 10.2967/jnumed.118.211359. Epub 2018 Apr 13.
8
Radiotheranostics in Cancer Diagnosis and Management.放射治疗诊断学在癌症诊断与管理中的应用
Radiology. 2018 Feb;286(2):388-400. doi: 10.1148/radiol.2017170346.
9
Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.分化型甲状腺癌放射性碘显像与治疗的若干争议
Endocrinol Metab Clin North Am. 2017 Sep;46(3):783-793. doi: 10.1016/j.ecl.2017.04.007. Epub 2017 Jun 29.
10
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.一种结合基因组改变和临床因素的新型甲状腺乳头状癌进展综合风险指数。
Oncotarget. 2017 Mar 7;8(10):16690-16703. doi: 10.18632/oncotarget.15128.
Zotero 插件